Antibodies
8 December 2008
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH8 December 2008
BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization8 December 2008
Immunomedics Reports Initial Results From Phase I/II Study of Veltuzumab in Immune Thrombocytopenic Purpura8 December 2008
Ablynx Expands Its Anti-Thrombotic Portfolio and Announces Initiation of a Phase I Study for ALX-06818 December 2008
Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients8 December 2008
Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma8 December 2008
ImmunoGen, Inc. Announces Favorable IMGN901 Clinical Findings Reported at ASH Annual Meeting6 December 2008
Seattle Genetics Reports Objective Responses with Dacetuzumab in Phase II Non-Hodgkin Lymphoma Trial6 December 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer5 December 2008
New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn’s Patients With Fistulizing Disease5 December 2008
YM Biosciences Provides EU Regulatory Update4 December 2008
MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor4 December 2008
Symphogen and Meiji Seika Kaisha Ltd. Achieve Milestone in Discovery Collaboration for Recombinant Polyclonal Antibody, Sym0062 December 2008
Morphotek(R) Inc. Announces Initiation of Farletuzumab Phase II Study In Platinum-Resistant Ovarian Cancer2 December 2008
Innate Pharma Announces The Entry Into Pre-clinical Validation of IPH 4201, a New Monoclonal Antibody Targeting Pancreatic Cancer28 November 2008
MedImmune Receives FDA Complete Response Letter on Motavizumab26 November 2008
Amorfix Successfully Completes ALS Drug Discovery Program26 November 2008
Arana commences ART621 Phase II rheumatoid arthritis trialNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports